Matthew Weston

Matthew Weston is an analyst at UBS, known for his insights into the pharmaceutical sector. Recently, he published a study highlighting the rapid market penetration of generics following the expiration of patents for major Novartis medications, forecasting significant impacts on the company's revenue from these changes.